FAQs
1. How soon after CAR T-cell therapy can patients return to normal daily activities?
Recovery after CAR T-cell therapy varies widely among patients. Many experience acute side effects such as fatigue, fever, and neurological symptoms that require close monitoring, often in a hospital setting for several days to weeks after infusion. Once stabilized, patients typically need several additional weeks to months for full immune recovery and resolution of side effects before resuming regular activities.
2. How accessible is CAR T-cell therapy globally?
Access to CAR T-cell therapy remains limited globally due to several factors: the high cost of manufacturing and clinical delivery, the need for specialized treatment centers with expertise in managing potentially severe side effects, regulatory hurdles, and logistical complexities in transporting customized CAR T-cell products.
3. Is age a barrier to receiving CAR T-cell therapy?
Age is not an absolute barrier. Clinical studies have shown CAR T-cell therapy to be safe and effective in older adults, with patient’s overall health and fitness being important considerations.
Reference
1. Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 11(4), 69.
2. Mellman, I., Coukos, G., & Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature, 480(7378), 480-489.
3. Liu, D. (2019). CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. Journal of Hematology & Oncology, 12(1), 113.
4. Li, C., Cao, W., Que, Y., et al. (2021). A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clinical and translational medicine, 11(3), e346.
5. Sun, L., Su, Y., Jiao, A., et al. (2023). T cells in health and disease. Signal transduction and targeted therapy, 8(1), 235.
6. Zhang, G., Wang, L., Cui, H., et al. (2014). Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Scientific reports, 4(1), 3571.
7. Hay, K. A., & Turtle, C. J. (2017). Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies. Drugs, 77(3), 237-245.
8. Roex, G., Timmers, M., Wouters, K., et al. (2020). Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Journal of hematology & oncology, 13(1), 164.
9. López-Cantillo, G., Urueña, C., Camacho, B. A., et al. (2022). CAR-T cell performance: how to improve their persistence?. Frontiers in Immunology, 13, 878209.
10. Liu, Y., Fang, Y., Chen, X., et al. (2020). Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Science immunology, 5(43), eaax7969.
11. Harrer, D. C., Heidenreich, M., Fante, M. A., et al. (2022). Apheresis for chimeric antigen receptor T‐cell production in adult lymphoma patients. Transfusion, 62(8), 1602-1611.
12. Tian, Y., Li, Y., Shao, Y., et al. (2020). Gene modification strategies for next-generation CAR T cells against solid cancers. Journal of hematology & oncology, 13(1), 54.
13. Bajgain, P., Tawinwung, S., D’Elia, L., et al. (2018). CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. Journal for immunotherapy of cancer, 6(1), 34.
14. Canelo-Vilaseca, M., Sabbah, M., Di Blasi, R., et al. (2025). Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. Bone Marrow Transplantation, 1-9.
15. Amini, L., Silbert, S. K., Maude, S. L., et al. (2022). Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature reviews Clinical oncology, 19(5), 342-355.
16. Reiser, V. (2020). Beyond CAR T-cell therapy: continued monitoring and management of complications. Journal of the Advanced Practitioner in Oncology, 11(2), 159.
17. Wu, Y., & Yu, X. Z. (2019). Modelling CAR-T therapy in humanized mice. EBioMedicine, 40, 25-26.
18. Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022). Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer gene therapy, 29(8), 1080-1096.
19. Chow, V. A., Shadman, M., & Gopal, A. K. (2018). Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood, The Journal of the American Society of Hematology, 132(8), 777-781.
20. Mohty, R., & Kharfan-Dabaja, M. A. (2022). CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Therapeutic Advances in Hematology, 13, 20406207221142133.
21. Zhang, X., Zhang, H., Lan, H., et al. (2023). CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Frontiers in immunology, 14, 1101495.
22. Giavridis, T., van der Stegen, S. J., Eyquem, J., et al. (2018). CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature medicine, 24(6), 731-738.
23. Gu, T., Hu, K., Si, X., et al. (2022). Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment. WIREs mechanisms of disease, 14(6), e1576.
24. Kochenderfer, J. N., & Rosenberg, S. A. (2013). Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature reviews Clinical oncology, 10(5), 267-276.
25. Fiorenza, S., Ritchie, D. S., Ramsey, S. D., et al. (2020). Value and affordability of CAR T-cell therapy in the United States. Bone marrow transplantation, 55(9), 1706-1715.
26. Amini, L., Silbert, S. K., Maude, S. L., et al. (2022). Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature reviews Clinical oncology, 19(5), 342-355.
27. Sureda, A., Adam, S. E., Yang, S., et al. (2024). Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals. Future Oncology, 20(36), 2855-2868.
28. Guzman, G., Reed, M. R., Bielamowicz, K., et al. (2023). CAR-T therapies in solid tumors: opportunities and challenges. Current oncology reports, 25(5), 479-489.
29. Yin, X., He, L., & Guo, Z. (2023). T‐cell exhaustion in CAR‐T‐cell therapy and strategies to overcome it. Immunology, 169(4), 400-411.
30. Sommer, C., Cheng, H. Y., Nguyen, D., et al. (2020). Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Molecular Therapy, 28(10), 2237-2251.
31. Saeed, H., Nesvisky, T., Kazmi, S., et al. (2025). Recent Advances in CAR-T Cell Therapy: from Dual Targeting To Emerging Innovations. Current Tissue Microenvironment Reports, 1-22.
32. Marofi, F., Motavalli, R., Safonov, V. A., et al. (2021). CAR T cells in solid tumors: challenges and opportunities. Stem cell research & therapy, 12(1), 81.
33. Brudno, J. N., & Kochenderfer, J. N. (2019). Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood reviews, 34, 45-55.
34. Ferreri, C. J., & Bhutani, M. (2024). Mechanisms and management of CAR T toxicity. Frontiers in Oncology, 14, 1396490.
35. Zhou, J., Lei, B., Shi, F., et al. (2024). CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Frontiers in Immunology, 15, 1476859.
36. Fischbach, F., Richter, J., Pfeffer, L. K., et al. (2024). CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med, 5(6), 550-558.
37. Qi, J., Ding, C., Jiang, X., et al. (2020). Advances in developing CAR T-cell therapy for HIV cure. Frontiers in Immunology, 11, 361.
38. Depil, S., Duchateau, P., Grupp, S. A., et al. (2020). ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nature reviews Drug discovery, 19(3), 185-199.
39. Short, L., Holt, R. A., Cullis, P. R., et al. (2024). Direct in vivo CAR T cell engineering. Trends in Pharmacological Sciences, 45(5), 406-418.
40. Moretti, A., Ponzo, M., Nicolette, C. A., et al. (2022). The past, present, and future of non-viral CAR T cells. Frontiers in immunology, 13, 867013.